GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Price-to-Free-Cash-Flow

BioLine Rx (BioLine Rx) Price-to-Free-Cash-Flow : N/A (As of May. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Price-to-Free-Cash-Flow?

As of today (2024-05-27), BioLine Rx's share price is $0.685. BioLine Rx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.38. Hence, BioLine Rx's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BioLine Rx's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, BioLine Rx's highest Price-to-Free-Cash-Flow Ratio was 6.86. The lowest was 0.00. And the median was 6.29.

BLRX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.53
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BioLine Rx's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.38.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 40.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 29.20% per year.

During the past 13 years, BioLine Rx's highest 3-Year average Free Cash Flow per Share Growth Rate was 51.70% per year. The lowest was 1.20% per year. And the median was 32.00% per year.


BioLine Rx Price-to-Free-Cash-Flow Historical Data

The historical data trend for BioLine Rx's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Price-to-Free-Cash-Flow Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioLine Rx's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, BioLine Rx's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Price-to-Free-Cash-Flow falls into.



BioLine Rx Price-to-Free-Cash-Flow Calculation

BioLine Rx's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.685/-0.382
=N/A

BioLine Rx's Share Price of today is $0.685.
BioLine Rx's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BioLine Rx  (NAS:BLRX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BioLine Rx Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023